Met Life Investment Management, LLC Aldeyra Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Aldeyra Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 28,689 shares of ALDX stock, worth $120,780. This represents 0.0% of its overall portfolio holdings.
Number of Shares
28,689
Previous 28,689
-0.0%
Holding current value
$120,780
Previous $94,000
63.83%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding ALDX
# of Institutions
117Shares Held
36.4MCall Options Held
196KPut Options Held
142K-
Perceptive Advisors LLC New York, NY9.28MShares$39.1 Million1.31% of portfolio
-
Knoll Capital Management, LLC Miami, FL5.48MShares$23.1 Million14.56% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.76MShares$15.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.62MShares$15.2 Million0.0% of portfolio
-
Kennedy Capital Management, Inc. St Louis, MO1.88MShares$7.92 Million0.24% of portfolio
About Aldeyra Therapeutics, Inc.
- Ticker ALDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,323,100
- Market Cap $246M
- Description
- Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...